Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 6

Country deep-dive

Can you import Retatrutide into the US?

Retatrutide is not FDA approved, cannot be compounded, and does not fit the ordinary personal-import route promoted by research sellers.

10 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

What Retatrutide actually costs in the US

No official US Retatrutide price exists because there is no FDA-approved pack. Seller quotes, trial supply and forecasts are different things.

10 Nov 2026 · PeptideMethods Editorial Team · 7 min read
Country deep-dive

Retatrutide US status: what changed

Retatrutide remains investigational and unapproved in the US. Phase 3 news and FDA enforcement messaging changed, not retail status.

10 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

Can you import Semaglutide into the US?

FDA-approved semaglutide exists in the US, but that does not make foreign pens, compounded vials or research products freely importable.

10 Nov 2026 · PeptideMethods Editorial Team · 7 min read
Explainer

DIAL2 risk after semaglutide

A two-year cohort tracked DIAL2-predicted risk after semaglutide, empagliflozin, or both. It did not measure cardiovascular events.

10 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

GLP-1 Drugs and the FDA Eye Warning

The FDA now requires GLP-1 drug labels to warn about a potential risk of NAION, a rare condition that can cause sudden vision loss.

10 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

What Kuwait Women Knew About GLP-1s

A Kuwait survey found high tirzepatide and semaglutide awareness, but sharp differences in information sources and risk perceptions.

10 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Foundayo and sleep apnea trial results

Two phase 3 trials found that oral orforglipron reduced sleep-apnea events, but the result is not a new FDA indication.

10 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Peptides and Male Sexual Dysfunction

A systematic review found the clearest erectile signal for melanocortin agonists, but the male evidence remains small, varied and short term.

10 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

GLP-1 weight loss: strength versus mass

A 2026 review argues that lean-mass scans cannot show whether GLP-1 weight loss is reducing strength or physical function.

9 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 Medicines, Uric Acid and Gout

A meta-analysis links GLP-1-based therapy with modest uric-acid reductions and fewer gout flares, but dedicated gout trials are still missing.

9 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

HIV weight care: GLP-1s and tesamorelin

A 2026 review separates general obesity care from HIV-specific evidence for GLP-1 therapies, tesamorelin and body-composition outcomes.

9 Nov 2026 · PeptideMethods Editorial Team · 4 min read